

# Revista Colombiana de Anestesiología

## Colombian Journal of Anesthesiology

www.revcolanest.com.co



### Review

## Current trends in the preoperative management of patients receiving warfarin for anticoagulation

Iván Mauricio Alvarado Arteaga\*

Anesthesiologist, San Ignacio University Hospital. Ad Honorem Professor, Pontificia Universidad Javeriana. Bogotá, Colombia

#### ARTICLE INFO

##### Article history:

Received: March 28, 2011

Accepted: November 22, 2011

##### Keywords:

Perioperative Period

Anticoagulants

Heparin

Thrombosis

#### ABSTRACT

**Introduction:** The perioperative management of patients receiving chronic treatment with warfarin and scheduled for invasive, elective or emergency procedures is a difficult and frequently arising problem in clinical practice. The lack of clear management guidelines and the indiscriminate use of the temporary replacement with unfractionated heparin creates delays, increases costs and unnecessarily prolongs the length of hospital stay.

**Objectives:** To review current trends and their supporting evidence of temporary replacement ("bridging") during the pre-operative period, emphasizing the use of low-molecular-weight heparins on an outpatient basis.

**Methodology:** PubMed search of evidence-based management guidelines, expert consensus and original trials.

**Results:** Three evidence-based clinical practice guidelines, together with multiple narrative expert reviews, four of them recently published, were identified. Clinical trials found in the surgical setting were purely observational. Although there are comparative studies, none of them apply to the surgical setting.

**Discussion:** Management evidence is limited and expert consensus guidelines are inconsistent.

**Conclusions:** There is suggestive, though non-conclusive evidence supporting the use of low-molecular-weight heparins for temporary replacement ("bridging") of pre-operative anticoagulation on an outpatient basis. There is a need to conduct well-designed comparative studies in the perioperative setting. Guidelines for anticoagulation management in elective and emergency cases are proposed on the basis of the information available, expressed in the form of a simple and innovative graphic algorithm applicable to the Colombian situation.

© 2012 Sociedad Colombiana de Anestesiología y Reanimación. Published by Elsevier.

All rights reserved.

\*Corresponding author at: Carrera 77 # 19 - 35, int. 2 apto. 702, Bogotá, Colombia.  
E-mail: alvaradoivancolombia@yahoo.com (I.M. Alvarado).

## Tendencias actuales en el manejo preoperatorio de pacientes anticoagulados con warfarina

### RESUMEN

#### Palabras clave:

Periodo perioperatorio  
Anticoagulantes  
Heparina  
Trombosis

**Introducción:** El manejo de la anticoagulación perioperatoria en pacientes tratados crónicamente con warfarina y programados para procedimientos invasivos, electivos y urgentes es un problema clínico frecuente y de difícil manejo. La ausencia de esquemas de manejo claros y el uso indiscriminado de remplazo transitorio con heparina no fraccionada genera demoras, sobre costos y días de hospitalización innecesarios.

**Objetivos:** Revisar las tendencias actuales y evidencia que las soporta, concerniente al remplazo transitorio de la anticoagulación en el preoperatorio ("puenteo"), con énfasis en el uso de heparinas de bajo peso molecular, de manera ambulatoria.

**Metodología:** Se realizó una búsqueda en PubMed de las guías de manejo basadas en la evidencia, consensos de expertos y estudios originales al respecto.

**Resultados:** Se identificaron tres guías de práctica clínica, basadas en la evidencia y múltiples revisiones narrativas por expertos, cuatro de ellas recientes. Los estudios clínicos encontrados en ámbito quirúrgico, son puramente observacionales. Existen estudios comparativos, pero en escenarios no quirúrgicos.

**Discusión:** La evidencia respecto al manejo es limitada y las guías por consenso de expertos son inconsistentes.

**Conclusiones:** Existe evidencia sugestiva, aunque no concluyente, que soporta la utilidad de las heparinas de bajo peso molecular; en el remplazo transitorio y ambulatorio de la anticoagulación en el preoperatorio ("puenteo"). Se necesitan estudios comparativos, bien diseñados, realizados en el ámbito perioperatorio. Con base en la información disponible, se proponen algunos lineamientos con respecto al manejo de anticoagulación en casos electivos y urgentes, expresándolos gráficamente en un algoritmo novedoso y sencillo.

© 2012 Sociedad Colombiana de Anestesiología y Reanimación. Publicado por Elsevier.

Todos los derechos reservados.

### Impact of the problem

Approximately 1.4% of the adult population requires continuous oral anticoagulation,<sup>1</sup> and this percentage may increase in the future.<sup>2</sup> Moreover, at least 10% of this population faces the possibility of a surgical intervention every year.<sup>3</sup> Maintaining the anticoagulation effect until the time of surgery or during the procedure may result in excess bleeding;<sup>3,4</sup> on the other hand, interrupting the treatment during the perioperative period increases the risk of thromboembolic events.<sup>5,6</sup> This creates a very common and difficult clinical problem that has already been the focus of attention in this journal.<sup>7,8</sup>

In order to overcome the problem, warfarin is usually interrupted several days prior to the intervention and replaced with the temporary use of anticoagulants of shorter action in order to minimize the time without anticoagulation effect. This bridging practice has been based traditionally on the use of unfractionated heparin (UH) as an intravenous infusion; however, this involves unnecessary hospitalizations and additional costs for patients, institutions and health systems alike.

A recent trend consists of the use of low-molecular-weight heparins (LMWH). Given the ease of subcutaneous administration and the predictability of their effect, they may be used on an outpatient basis and reduce costs and hospital stay. However, there are doubts and some confusion among

clinicians involved in perioperative management regarding their effectiveness, safety and form of use.

Some scientific societies worldwide have gathered the literature available in an attempt at formulating management schemes in the form of evidence-based clinical guidelines,<sup>9-11</sup> and there are also numerous expert narrative reviews on the subject.<sup>12-15</sup> Unfortunately, there is no consensus regarding the recommendations, and the proposed schemes tend to be exceedingly complex or inapplicable.

The aim of this paper is to mention the most relevant evidence supporting current management trends for elective and emergency cases in the preoperative period that usually involve the treating anesthetist, and to propose a simple algorithm (fig. 1) that tries to summarize the international recommendations, and that may be applicable in the Colombian setting.

### Considerations of the variables and risks

Among multiple factors that need to be considered, the two most important variables in decision-making during the preoperative period are the risk of bleeding associated with the procedure, and the risk of thromboembolic events associated with the patient. The former determines the need for timely interruption of warfarin, and the latter affects the relevance of bridging and the dose.




Fig. 1 – Algorithm for pre-surgical patients anticoagulated with warfarin.

Source: prepared by the authors

Risks must be assessed in terms of probability and clinical repercussions (morbidity and mortality).<sup>15</sup> Using risk prediction scales, risks are classified according to severity in order to establish relevant cut-off points for decision-making. At present, predicting the risk of thromboembolic events has been more consistent than predicting the risk of bleeding.

### Prediction of the risk of perioperative bleeding

It has been estimated that the risk of death associated with major bleeding due to cumadin ranges between 3% and 9%.<sup>4,9</sup> The effect on morbidity is also significant in terms of emergency surgery, adverse cardiac and respiratory events, increased risk of infection, and potential long-term consequences associated with the healing process, and chronic pain.<sup>4,14</sup> Moreover, bleeding may delay the restart of anticoagulation, increasing the time at risk for thromboembolic events.<sup>16</sup>

Depending on the proposed procedure, multiple scales have been designed for predicting perioperative bleeding,<sup>12,14</sup> but they show serious inconsistencies in terms of the number of groups and the cut-off points. More worrisome still is their low predictive value, perhaps due to the wide variety of additional factors involved.

Consequently, careful classification of a procedure in a given group would hardly be relevant for preoperative planning. In contrast, it is more practical to establish a cut-off point with implications for management, and to separate the procedures that may be undertaken without interrupting warfarin from those that require interruption and, potentially, bridging.

### Practice based on the risk of bleeding

There are minimally invasive procedures in dentistry, ophthalmology, dermatology and endoscopic practice that are usually associated with negligible bleeding which does not increase with full oral anticoagulation.

The way to proceed, based on prospective randomized studies in dentistry,<sup>17,18</sup> as well as on prospective cohort studies in the other areas,<sup>19-21</sup> would be to continue with full anticoagulation during the perioperative period without using bridging agents, all in accordance with the guidelines and expert opinions.<sup>9-15</sup> Not all "minor surgeries" may be included in this group, but only those listed in table 1. Exceptions to the rule include the surgeon's reluctance to perform the procedure with the patient under anticoagulation, and procedures planned for regional anesthesia (neuroaxial, plexus or ocular blocks).<sup>22,23</sup>

All other surgical procedures involve some risk of bleeding where the severity and clinical repercussions may increase as a result of oral anticoagulation.<sup>3,4</sup> On the other hand, other procedures may cause minor bleeds in terms of quantity, but with serious local repercussions that may increase with anticoagulation, such as those involving the central nervous system, the posterior chamber of the eye, polypectomies larger than 2 cm,<sup>25</sup> prostate biopsies,<sup>26</sup> pacemaker or defibrillator implantations.<sup>27</sup>

Warfarin must be interrupted on a timely basis, in accordance with the guidelines, practically for every elective

**Table 1 - Procedures associated with a minimal risk of bleeding which does not increase with full anticoagulation**

- Minor dentistry procedures: treatment of cavities, gums and simple tooth extractions.
- Endoscopic procedure of the upper and lower GI tract even including biopsy (exclude if polypectomy is involved). ERCP, even if it includes stent placement (exclude if it involves sphincterotomy).
- Minor superficial dermatological procedures such as excisional biopsies and Mohs surgery.
- Minor invasive ophthalmological procedures of the anterior chamber under topical anesthesia: cataract extraction with intra-ocular lens implantation.
- Exclusions refer to procedures requiring regional neuroaxial anesthesia or plexus or retro/peribulbar blocks.

Fuente: Autores a partir de: Dunn AS(4), Douketis JD(9), Jeske AH (17), Bacci C(18), Eisen GM (19), Hirschman DR (20), Katz J (21), Kallio H (22), Horlocker TT (23)

procedure involving a risk of bleeding (except for those listed in table 1) or whenever regional anesthesia is planned.<sup>9-15</sup> The additional need for bridging and the possible bridging regimes will be discussed later.

### Predicting the risk of preoperative thromboembolic events

The clinical conditions that warrant continuous anticoagulation with warfarin are mainly three: chronic atrial fibrillation (AF), prosthetic heart valves, and a history of venous or pulmonary thromboembolism (DVT-PTE). They each represent a heterogeneous group of thromboembolic risk that varies depending on the history of prior events, comorbidities, and associated conditions.

In chronic AF, the risk increases with a valve substrate; if not, the risk depends on associated factors quantified according to the CHADS2 scale.<sup>28,29</sup> The risk with prosthetic valves increases when they are of an older generation, when they are in the mitral or tricuspid position, and as a result of other factors similar to CHADS2.<sup>11,30</sup> In DVT or PTE, the risk varies according to the time elapsed since the event, the number of recurrences, and the presence and severity of underlying thrombophilic conditions.<sup>31,32</sup>

For practical considerations, these conditions may be regrouped on a baseline thromboembolic risk scale according to the annual probability of a patient having an event if not anticoagulated. Consequently, the risk may be classified as *low* if it is lower than 4%; *moderate* if it ranges between 4% and 10%; and *high* if it is greater than 10% (fig. 2).<sup>9</sup> The clinical impact must also be taken into consideration. In that regard, the impact of an arterial thrombosis (chronic AF or prosthetic valves) is greater in terms of quality of life and mortality, when compared to venous thrombosis (DVT-PTE).<sup>32,33</sup>

	Deep venous thrombosis or pulmonary thromboembolism (DVT-PTE)	Chronic atrial fibrillation (CAF)	Mechanical cardiac prosthetic valve
High risk	DVT-PTE less than 3 months or associated severe pro-clotting condition (protein C, S or antithrombin deficit, Sd antiphospholipid or multiple abnormalities)	CAF with rheumatic valvulopathy CAF with thrombosis TIA less than 3 months Non valvular CAF CHADS <sub>2</sub> scale 5 or 6*	Mitral, tricuspid or old generation mechanical prosthesis (basket balloon or swing disk) or associated with arterial venous episode or TIA less than 6 months
Moderate risk	DVT-PTE between 3-12 months or recurrent / non-severe associated pro-clotting condition (heterozygous Leyden factor V like, mutation factor II) or with active cancer (palliative or treated less than 6 months before)	Non-valvular CAF, CHADS <sub>2</sub> scale 3 or 4	New generation aortic mechanical prosthesis (bi-leaflet), with CAF or any CHADS associated risk factor
Low risk	Single DVT-PTE, over 12 months, no underlying pro-clotting condition	Non valvular CAF, CHADS <sub>2</sub> scale 0 to 2 and no history of thrombosis or TIA	New generation (bi-leaflet) Mechanical aortic prosthesis, with no associated risk factors

\*Risk scale for chronic, non-valvular atrial fibrillation: CHADS<sub>2</sub>  
(Congestive heart failure-Hypertension-Age-Diabetes-Stroke)

History of congestive heart failure	1 punto
Hypertension	1 punto
Diabetes Mellitus	1 punto
Age over 75 years	1 punto
History of CVA or TIA	2 punto

**Fig. 2 – Stratification of thromboembolic risk**

Source: adapted from Douketis, J. D. et al., 2008; Gage B. F. et al., 2001.

In mathematical terms, the risk for every day that goes by without anticoagulation during the perioperative period would be equal to the annual baseline risk divided by 365.<sup>9</sup> Some authors mention an additional risk element related to a transient hypercoagulability condition resulting from the abrupt interruption of warfarin.<sup>34</sup> Although the type of surgery affects the risk of a thromboembolic event,<sup>35</sup> it is not an additional factor that would need to be considered during the preoperative period.

Recently, an analytical decision model suggests a cut-off point above 5.6% for the annual baseline risk in order to consider bridging,<sup>36</sup> which could be equated to the moderate and high risk groups.

### Strategies for reducing the preoperative risk of thromboembolism

After a recent venous thromboembolic event, the risk of recurrence drops dramatically during the first three months, hence the suggestion by some authors of deferring non-priority surgeries for at least 1 month, ideally 3 months. This suggestion could be extended to recent arterial or cardioembolic events.<sup>28</sup> The placement of a temporary caval filter is a possibility to consider in very recent DVT and in non-deferrable major surgery.<sup>32,37</sup>

Regarding the true usefulness of perioperative bridging, there are no prospective, randomized or placebo-controlled studies to date showing reliable information about its efficacy, safety, dose or comparative differences between potential drugs and regimes. The existing evidence is derived from good-quality studies, but there is a tendency to extrapolate it to the perioperative setting from non-surgical situations and lower quality studies (purely observational).

In non-surgical areas, there is good-quality evidence supporting the usefulness of LMWH for the management of DVT-PTE, and for reducing the risk of recurrence after an event. They have been shown to lend themselves to outpatient management because of their safety profile, and they have even been shown to be better than UFH.<sup>32</sup> The evidence supporting the use of LMWH for the control of arterial or cardioembolic events is less strong, although there is indirect evidence suggesting its usefulness in the management of chronic AF,<sup>38</sup> subacute ischemic stroke,<sup>39</sup> and also in cases of prosthetic valves, this is a more controversial issue.<sup>40</sup>

In the perioperative setting, there are no randomized controlled trials providing reliable evidence on the usefulness of bridging with LMWH; however, there are multiple descriptive prospective cohort studies showing a low mean rate of thromboembolic events (1%) and major bleeding (3%). In prosthetic valves, there are at least 14 studies with 1,300 patients showing an overall rate of thromboembolic events of 0.83%; in chronic AF, 10 studies

with 1,400 patients show a rate of 0.57%; and in DVT-PTE, 9 studies with 500 patients show an overall rate of 0.6%. The data were consolidated in a recent review by the ACCP.<sup>9</sup> There are two ongoing good-quality studies that are expected to provide more reliable information by 2014.<sup>41,42</sup>

The usefulness of unfractionated heparin (UFH) as a perioperative bridging agent is also supported by a smaller number of purely observational studies. A multi-center prospective non-randomized cohort study comparing perioperative bridging with UFH versus LMWH did not show significant differences in terms of thromboembolism or bleeding rates.<sup>43</sup> Although no differences were found in a subgroup analysis of prosthetic valves,<sup>44</sup> some cardiology societies still express their reservations regarding the use of LMWH in high-risk prosthetic valves.<sup>11</sup>

Regarding the bridging dose of LMWH, evidence-based guidelines.<sup>9-11</sup> are consistent in suggesting therapeutic doses of LMWH in high-risk groups, and prophylactic doses or no bridging in low-risk groups, although there are some inconsistencies in relation to the moderate risk of venous thromboembolism.

Out of simplicity and due to medical and legal reasons, an attempt should be made at unifying the recommendations around a more aggressive approach as that suggested by the best known guidelines: prophylactic doses for low-risk groups, and therapeutic doses for moderate and high-risk groups.<sup>9</sup>

### Practical protocol for pre-operative outpatient bridging with LMWH

Based on pharmacological studies of these drugs,<sup>45</sup> clinical trials on perioperative bridging<sup>16</sup> and the guidelines mentioned above, the following parameters could be suggested: warfarin interruption 4 to 5 days prior to surgery<sup>9-15</sup> (although a longer time period might be required in certain situations such as, an INR greater than 3, an elderly patient, decompensated heart failure and active cancer);<sup>46</sup> initiation of LMWH 24 to 36 hours after the last dose of warfarin (3 days before the procedure).<sup>9-15</sup> The most commonly used drugs, included in the Colombian mandatory health plan, are cited in the algorithm (fig. 1).

A twice-daily dose is preferable over single daily dose regimes for therapeutic doses.<sup>47</sup> Prophylactic and therapeutic treatment must be interrupted 12 hours and 24 hours before the procedure or regional anesthesia, respectively.<sup>9-15,23</sup> Given the erratic clearance of warfarin, an INR lower than 1.5 must be documented before surgery;<sup>9-15</sup> some authors suggest measuring the INR one day prior to surgery, in order to allow the possibility to correct an abnormal result with low-dose oral vitamin K (1-2.5 mg), thus avoiding the need to postpone surgery or the unwarranted administration of plasma.<sup>48</sup>

### Warfarin reversion in emergency cases

In cases of emergency surgery, a dose of 2.5-5 mg of vitamin K given orally or as a slow intravenous infusion may revert the anticoagulation effect of warfarin within 12 to 24 hours.<sup>49</sup> When the surgery is to be performed within a shorter period

of time, it is important to consider, aside from vitamin K, a dose of 10 ml/kg-15ml/kg of fresh frozen plasma (FFP).<sup>50</sup> However, its processing and administration take time, and it is also associated with transfusion risks (transfusion acute lung injury or TRALI, excess fluid burden, risk of infection, anaphylactic reactions); moreover, it might be insufficient in reverting hyper-anticoagulation states.

The use of prothrombin complex concentrate has been introduced recently at a dose of 25 IU/kg-50 IU/kg that appears quite promising, with comparative advantages over the use of FFP, it being faster, safer and more effective, and lacking the adverse effects associated with the use of FFP. However, its use is still limited because of its high cost and the scant evidence in the perioperative setting.<sup>51,52</sup>

### Competing Interests

None declared.

**Funding sources:** The author's own resources.

### REFERENCES

1. Bevan F, Brookes M, Colebrook R, et al. The assumptions used in estimating a benchmark rate of population requiring anticoagulation therapy per year. National institute for Health and Clinical Excellence [internet]. 2010 [citado: 10 de febrero del 2011]. Disponible en: <http://www.nice.org.uk/usingguidance/commissioningguides/anticoagulationtherapyservice/popbench.jsp>.
2. Friberg J, Gislason GH, Gadsbøll N, et al. Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation. *J Intern Med*. 2006;259:173-8.
3. McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. *Med Clin North Am*. 2001;85:1277-310.
4. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. *Ann Intern Med*. 2003;139:893-900.
5. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. *Arch Intern Med*. 2003;163:901-8.
6. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. *Stroke*. 2009;40:235-40.
7. Rincón PG. Anticoagulación y anestesia, caso clínico. *Rev Colomb Anesthesiol*. 1987;15:291-6.
8. Valencia W, Husbands JS. Tromboembolismo venoso postoperatorio: grave riesgo prevenible. *Rev Colomb Anesthesiol*. 2010;38:499-507.
9. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133 (6 Suppl):S299-339.
10. Spyropoulos AC, Douketis JD. Guidelines for antithrombotic therapy: periprocedural management of antithrombotic therapy and use of bridging anticoagulation. *Int Angiol*. 2008;27: 333-43.
11. Bonow RO, Carabello BA, Chatterjee K, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into

- the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. *J Am Coll Cardiol.* 2008;52:1-142.
12. Spyropoulos AC. To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures. *J Thromb Thrombolysis.* 2010;29:192-8.
  13. Jaff MR. Chronically anticoagulated patients who need surgery: can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin? *Catheter Cardiovasc Interv.* 2009;74 Suppl 1:S17-21.
  14. Douketis JD, Bakhsh E. Perioperative management of antithrombotic therapy. *Pol Arch Med Wewn.* 2008;118:201-8.
  15. O'Donnell M, Kearon C. Perioperative management of oral anticoagulation. *Cardiol Clin.* 2008;26:299-309.
  16. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. *Arch Intern Med.* 2004;164:1319-26.
  17. Jeske AH, Suchko GD. Lack of a scientific basis for routine discontinuation of oral anticoagulation therapy before dental treatment. *J Am Dent Assoc.* 2003;134:1492-7.
  18. Bacci C, Maglione M, Favero L, et al. Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case-control study. *Thromb Haemost.* 2010;104:972-5.
  19. Eisen GM, Baron TH, Dornitz JA, et al. American Society for Gastrointestinal Endoscopy. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. *Gastrointest Endosc.* 2002;55:775-9.
  20. Hirschman DR, Morby LJ. A study of the safety of continued anticoagulation for cataract surgery patients. *Nurs Forum.* 2006;41:30-7.
  21. Katz J, Feldman MA, Bass EB, et al. Study of Medical Testing for Cataract Surgery Team. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. *Ophthalmology.* 2003;110:1784-8.
  22. Kallio H, Paloheimo M, Maunuksela EL. Haemorrhage and risk factors associated with retrobulbar/peribulbar block: a prospective study in 1383 patients. *Br J Anaesth.* 2000;85:708-11.
  23. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). *Reg Anesth Pain Med.* 2010;35:64-101.
  24. Syed S, Adams BB, Liao W, et al. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. *J Am Acad Dermatol.* 2004;51:955-7.
  25. Sorbi D, Norton I, Conio M, et al. Postpolypectomy lower GI bleeding: descriptive analysis. *Gastrointest Endosc.* 2000;51:690-6.
  26. Ihezue CU, Smart J, Dewbury KC, et al. Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications. *Clin Radiol.* 2005;60:459-63.
  27. Wiegand UK, Lejeune D, Boguschewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. *Chest.* 2004;126:1177-86.
  28. Couillard P, Poppe AY, Coutts SB. Predicting recurrent stroke after minor stroke and transient ischemic attack. *Expert Rev Cardiovasc Ther.* 2009;7:1273-81.
  29. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA.* 2001;285:2864-70.
  30. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126 (3 Suppl):S457-82.
  31. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med.* 2000;160:761-8.
  32. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126 (3 Suppl):S401-28.
  33. Longstreth WT Jr, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. *Neurology.* 2001;56:368-75.
  34. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. *Curr Med Res Opin.* 2006;22:471-81.
  35. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. *N Engl J Med.* 1997;336:1506-11.
  36. Dunn AS, Wisnivesky J, Ho W, et al. Perioperative management of patients on oral anticoagulants: a decision analysis. *Med Decis Making.* 2005;25:387-97.
  37. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. *Blood Rev.* 2005;19:179-202.
  38. Amadeus Investigators, Bousser MG, Bouthier J, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. *Lancet.* 2008;371:315-21.
  39. Kalafut MA, Gandhi R, Kidwell CS, et al. Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia. *Stroke.* 2000;31:2563-8.
  40. Shapira Y, Sagie A, Battler A. Low-molecular-weight heparin for the treatment of patients with mechanical heart valves. *Clin Cardiol.* 2002;25:323-7.
  41. Ortel TL, Hasselblad V. A double blind randomized control trial of post-operative low molecular weight heparin bridging therapy versus placebo bridging therapy for patients who are at high risk for arterial thromboembolism (PERIOP-2). Canadian Institutes of Health Research (CIHR) [internet]. 2011 [citado: 10 de febrero de 2011]. Disponible en: URL : <http://www.clinicaltrials.gov/ct2/show/NCT00432796?term=periop&rank=1>
  42. Ortel TL, Hasselblad V. Effectiveness of bridging anticoagulation for surgery (The BRIDGE Study). National Heart, Lung, and Blood Institute (NHLBI) [internet]. 2009 [citado: 10 de febrero de 2011]. Disponible en: URL : <http://www.clinicaltrials.gov/ct2/show/NCT00786474?term=bridge&rank=26>
  43. Spyropoulos AC, Turpie AG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. *J Thromb Haemost.* 2006;4:1246-52.
  44. Spyropoulos AC, Turpie AG, Dunn AS, et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). *Am J Cardiol.* 2008;102:883-9.
  45. Ansell J, Hirsh J, Hylek E, et al. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based

- Clinical Practice Guidelines (8th Edition). Chest. 2008;133 (6 Suppl):S160-98.
46. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. *Ann Intern Med.* 2001;135:393-400.
  47. Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. *Thromb Haemost.* 2001;86:980-4.
  48. Woods K, Douketis JD, Kathirgamanathan K, et al. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. *J Thromb Thrombolysis.* 2007;24:93-7.
  49. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. *Arch Intern Med.* 2003;163:2469-73.
  50. Spence RK. Clinical use of plasma and plasma fractions. *Best Pract Res Clin Haematol.* 2006;19:83-96.
  51. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. *Am J Hematol.* 2008;83:137-43.
  52. Demeyere R, Gillardin S, Arnout J, et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. *Vox Sang.* 2010;99:251-60.